Background Gemcitabine (GEM), oxaliplatin plus GEM (OX + GEM), cisplatin plus GEM (CIS + GEM), capecitabine plus GEM (CAP + GEM), FOLFIRINOX (FFX), and nab-paclitaxel plus GEM (NAB-P + GEM) are the most commonly used regimens as first-line treatment of metastatic pancreatic cancer (MPC) in the UK. Independent economic evaluation of these regimens simultaneously has not been conducted for the UK. Objective Using data from a network meta-analysis as efficacy measures, we estimated the cost effectiveness and cost utility of these regimens for the UK. Methods A three-state Markov model (progression-free, progressed-disease, and death) simulating the total costs and health outcomes (quality-adjusted life-years [QALYs] gained and life-years [LYs]) was developed to estimate the incremental costutility (ICUR) and incremental cost-effectiveness ratios (ICER) for patients with MPC, from the payer perspective. The model was specified to calculate total costs in 2017 British pounds (GBP, £). All values were discounted at 3.5% per year over a full lifetime horizon. One-way sensitivity and probabilistic sensitivity analyses were conducted to assess the impact of parameter uncertainty on the results. Results FFX was the most effective regimen, NAB-P + GEM was the most costly regimen, and GEM was the least costly and least effective regimen. OX + GEM, CIS + GEM, and NAB-P + GEM were dominated by CAP + GEM and FFX. Compared with GEM, the ICUR for CAP + GEM and FFX was £28,066 and £33,020/QALY gained, respectively; compared with GEM, the ICER for CAP + GEM and FFX was £17,437 and £22,291/LY gained, respectively; and compared with CAP + GEM, the ICUR and ICER for FFX were £34,947/QALY gained and 24,414/LY gained, respectively. Conclusions At a threshold value of £30,000/QALY, CAP + GEM was found to be the only cost-effective regimen in the management of MPC in the UK. 
Introduction
Pancreatic cancer is the tenth most commonly diagnosed cancer and fifth most common cause of cancer-related mortality in the UK, accounting for 3% of all new cancer cases. In the UK, 9400 patients were diagnosed with pancreatic cancer in 2013, while 8700 died of the disease in 2012 [1] . The 1-and 5-year survival rates were 21.5 and 5.3%, respectively, the lowest of the major cancers [1, 2] . Surgical resection is the only curative treatment for pancreatic cancer, but only 10% of cases are eligible for surgery as most are diagnosed in the advanced and metastatic stages [2] . Chemotherapy with gemcitabine (GEM) has been the standard of care since 1997, when a randomized controlled trial found a prolonged median overall survival (OS) of 4.4-5.7 months and an improvement in the clinical benefit response (4.8 vs. 23 .8%) for GEM over 5-fluorouracil [3, 4] .
Several GEM combination therapies, including capecitabine (CAP), oxaliplatin (OX), and cisplatin (CIS), have been evaluated since the introduction of GEM as standard of care [5] . Phase III clinical trials of these combination therapies failed to show a statistically significant OS improvement over GEM; however, a meta-analysis showed a statistically significant improvement in OS for OX + GEM (odds ratio [OR] 1.33; p = 0.019) and CAP + GEM (OR 1.33; p = 0.007), but not for CIS + GEM over GEM [5, 6] . In 2011, FOLFIRINOX (FFX) produced superior OS (11.1 vs. 6.8 months; hazard ratio [HR] 0.57; p < 0.001), progression-free survival (PFS; 6.4 vs. 3.3 months; HR 0.47; p < 0.001), and response rate (31 vs. 9 .4%) over GEM [7] . In 2013, albumin-bound paclitaxel (nab-paclitaxel [NAB-P]) in combination with GEM showed a statistically significant improvement in OS (8.5 vs. 6.7 months; HR 0.72; p < 0.001), PFS (5.5 vs. 3.7 months; HR 0.69; p < 0.001), and overall response rate (23 vs. 7%) over GEM [8] . Considering these various treatment options, the variability in OS and PFS, as well as safety and differences in total costs of treatment, economic evaluations are indicated.
We recently reviewed 16 published economic evaluations of chemotherapy regimens for metastatic pancreatic cancer (MPC) [9] , including 5-fluorouracil, GEM, CAP + GEM, erlotinib plus GEM (E+ GEM), FFX, NAB-P + GEM, tegafur/gimeracil/oteracil potassium (S-1), and S-1 + GEM. Seven evaluations were specific to the UK, including four focusing on GEM versus 5-fluorouracil, two focusing on NAB-P + GEM versus GEM, and one focusing on NAB-P + GEM, CAP + GEM, and FFX versus GEM. One key conclusion was that assessments of cost and benefits are determined by local market determinants and therefore need to be evaluated for each market separately. To date, there have been no comprehensive economic evaluations of all systemic chemotherapy regimens for MPC for the UK.
Independent economic evaluations are pertinent for the UK because of the role of health technology assessment in treatment access decisions. This was brought to the fore in the case of NAB-P + GEM. The first economic evaluation was submitted by the manufacturer as part of its National Institute for Health and Care Excellence (NICE) dossier; NICE referred this analysis to an Expert Review Group (ERG) for a repeat analysis [10] . The third economic evaluation was an independent analysis by our group [11] .
The manufacturer's economic evaluation compared NAB-P + GEM, FFX, and CAP + GEM with GEM, using NAB-P + GEM as the base-case treatment. In the absence of direct comparative trial evidence, the efficacy data for the comparator treatments (FFX, CAP + GEM, and GEM) were obtained from an unpublished network meta-analysis. The proportional hazard assumption was assumed to be valid; that is, for any pairwise comparison, the hazard rate on one arm is proportional to the hazard rate on the other arm, which maintains consistency over time. US-based utility estimates were used. The estimated incremental costutility ratio (ICUR), measured in British pounds (GBP, £) per quality-adjusted life-year (QALY) gained, was £51,900/ QALY gained for NAB-P + GEM over GEM, and £87,084/ QALY gained for NAB-P + GEM over CAP + GEM. Compared with FFX, it was determined that NAB-P + GEM was more costly, with an incremental cost of £3109, and less effective, with incremental QALYs of − 0.144.
In its review, the NICE ERG challenged the validity of the proportional hazard assumption between NAB-P + GEM and CAP + GEM and FFX [10] . It was suggested that utilities be adjusted to 0.742 (from 0.800) for progression-free disease and 0.671 (from 0.750) for progressed disease, to reflect the UK context. The ERG estimated the ICUR at £78,488/ QALY gained.
Our UK economic evaluation of NAB-P + GEM versus GEM [11] , using Canadian utility estimates and NAB-P + GEM set as the base-case treatment, yielded an ICUR of £78,084/QALY gained and an ICER of £30,367/ life-year (LY) gained for NAB-P + GEM over GEM. Our ICUR estimate was very close to the ERG estimates, both of which differed significantly from those in the manufacturer's NICE dossier.
To date, there have been no comprehensive randomized trials comparing the multiple treatment options for MPC simultaneously, hence indirect estimates of comparative efficacy are needed to support an economic evaluation. Gresham and colleagues conducted a network meta-analysis for all systemic chemotherapies (OX + GEM, CIS + GEM, CAP + GEM, NAB-P + GEM and GEM) against FFX [12] . FFX was found to have superior OS efficacy over GEM, CAP + GEM, CIS + GEM, and OX + GEM, but not over NAB-P + GEM. Additionally, superior PFS efficacy was determined over GEM, CAP + GEM, CIS + GEM, OX + GEM, and NAB-P + GEM. The indirect comparison of clinical outcomes in the Gresham et al. [12] network metaanalysis provided the platform for the independent economic evaluation reported here. Specifically, we assessed the comparative cost utility and cost effectiveness of OX + GEM, CIS + GEM, CAP + GEM, FFX, and NAB-P + GEM against GEM. Note that CIS + GEM was included in our analysis because this regimen's use persists in the UK even though its efficacy is not statistically different from GEM [13] . We used UK-specific utilities for the estimation of QALYs in as far as was available.
Methods

Patient Population
This economic evaluation utilized, as the analysis cohort, the characteristics of the patient samples of applicable phase III clinical trials. This primarily included adults recently diagnosed with metastatic or advanced ductal adenocarcinoma of the pancreas with no prior chemotherapy for metastatic disease [7, 8, [14] [15] [16] [17] [18] [19] [20] (for characteristics of patients included in the studies, see Electronic Supplementary Table S1 ). Patients diagnosed with pancreatic cancer in the UK were slightly older than those included in the clinical trials.
Model Structure and Design
A Markov state transition model was constructed for a hypothetical cohort of patients with MPC (Electronic Supplementary Fig. S1 ). The model was based on the OS and PFS Kaplan-Meier curves and included the following health states (henceforth denoted in italics): progressionfree, progressed-disease, and death. Patients start in the progression-free health state and, from time point to time point, can either stay in this health state, proceed to the progressed-disease state, or expire (death). Patients experiencing progressed-disease may either stay in this health state or expire. Note that the model assumes that patients leaving a given health state can never return to it, which is clinically valid.
The model was specified to calculate total costs (in 2017 £), QALYs, and LYs for all regimens. These were used to estimate the ICURs and ICERs for each regimen against each of the other regimens.
To fully incorporate the costs associated with the chemotherapy regimens, a 1-week Markov cycle length was used. The model considered the costs from the payer perspective over a lifetime horizon. All costs and outcomes were discounted at 3.5% per year. A bespoke model was created using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA).
Efficacy
The network meta-analysis [12] used FFX as the base-case treatment, and all other regimens were indirectly compared to it. For this reason, we set FFX as the base-case treatment in this model design, and GEM, CAP + GEM, CIS + GEM, OX + GEM, and NAB-P + GEM as the comparator treatments. Data on FFX OS and PFS were calculated from the Kaplan-Meier estimates of the phase III trial [7] using a digitizing program (TechDigs 2.2 IUCr, Chester, UK). The Weibull distribution was retained to calculate the OS and PFS data for FFX and to extrapolate the data over a lifetime horizon. The proportion of patients in the progression-free state at each cycle was calculated directly from the PFS curve; the proportion of patients in the death state at each cycle was calculated by subtracting the proportion survived from 1; and the proportion of patients in the progresseddisease state at each cycle was calculated by subtracting the proportion of patients in the other two health states from 1. The time-dependent transition probability at every week was calculated using the survival function of the Weibull distribution (Eq. 1) [21] :
where S(t) is the survival function, λ is the scale, γ is the shape parameter for the Weibull distribution, and t is the time.
Since the OS and PFS data for CAP + GEM, CIS + GEM, and OX + GEM were reported across several trials, it was not possible to assess the proportional hazard assumption
between these regimens and FFX. Hence, OS and PFS data for those regimens were obtained indirectly from the network meta-analysis [12] using the HRs reported. OS and PFS data for NAB-P + GEM were reported in one clinical trial [8] . The proportional hazard assumption of NAB-P + GEM against FFX was tested using the log-cumulative hazards plot.
Model Validation
The model was validated using Parts A, B, and C of the Assessment of the Validation Status of Health-Economic decision models [22] . For Part A (validation of the conceptual model), the conceptual model was judged appropriate by an oncologist with more than 20 years of experience in practice in terms of representing the underlying clinical disease stages and the ability to capture the benefit of the treatment based on these stages in the economic evaluations. The model is common to many economic models in the field of oncology and was utilized in all studies identified in our critical review of economic evaluations of treatments for pancreatic cancer [9] . The model was cross-validated against all these models and was found to be valid.
For Part B (input data validation), parameter inputs were validated with the same oncologist and were judged to be appropriate to the target population. The validity of the disease progression probabilities based on survival curves were tested using R 2 and residual sum of squares tests. The Weibull distribution was deemed to be valid, as based on the work of Gharaibeh et al. [23] .
Lastly, for Part C (validation of the computerized model), the total number of patients at each cycle was doublechecked and found to be equal at any point of the model. Model parameter inputs are detailed in Table 1 . The critical review of economic evaluations of treatments for pancreatic cancer [9] by our group served as the main reference to inform our model parameters.
Cost Inputs
Costs associated with each health state included those of the chemotherapy regimen, premedication, administration, adverse event management, monitoring, and testing. Assuming a mean body surface area of 1.83 m 2 [24] , the acquisition costs of chemotherapy and premedication were estimated using the 2017 British National Formulary (BNF) cost per milligram of chemotherapy, and assumed no wastage [25] . The targeted dose reported in clinical trials was multiplied by the dose intensity to calculate the actual dose. National Health Service (NHS) reference costs (2014/15) were applied to estimate the cost of chemotherapy administration and the treatment of adverse drug reactions [26] . Patients were assumed to be managed as day cases and not admitted to the hospital for drug administration. A secondary analysis included the cost of wastage, i.e. the cost of utilizing half a vial of chemotherapy was assumed to have the same cost as utilizing the whole vial.
Grade 3/4 nausea and vomiting, diarrhea, fatigue, and anemia were considered unlikely to require a full day of hospitalization and were treated as day cases. Peripheral neuropathy was considered to be managed by dose reduction and was covered by the relative dose intensity used in the model. Febrile neutropenia was treated as requiring hospitalization. Probabilities of adverse events per treatment may be found in the economic model platform submitted as Electronic Supplementary Material (ESM).
Costs related to patient monitoring, QALYs, and LYs were calculated for the simulation, and the process was repeated 2000 times, at which time the simulations reached saturation and ceased generating differing ICUR values. Costs related to patient monitoring were estimated using NHS reference costs (2014/2015) and Personal Social Services Research Units [26, 27] . Monitoring for patients in the progression-free health state while receiving first-line treatment was assumed to include one medical oncologist visit, one complete blood count and full biochemistry tests (including electrolytes every 4 weeks), and one cancer antigen (CA) 19-9 test every 8 weeks. Patients in the progression-free health state but not receiving first-line treatment did not receive active therapy but were assumed to require monitoring by one nurse visit per week (hospice care). Patients in the progressed-disease health state were assumed to receive one medical oncologist visit, one complete blood count test and full biochemistry tests (including electrolytes), one computerized tomography scan of more than three areas, and a CA19-9 test every 8 weeks. These assumptions were validated by a medical oncologist in the UK. All costs not reported in 2017 GBP were inflated using the UK Consumer Price Index [28] .
Health-Related Quality-of-Life Utilities
Utility decrement estimates for grade 3/4 adverse events for a representative sample of the UK population were obtained from the published literature [29] [30] [31] [32] . The exception was neuropathy pain, for which a Canadian population estimate was used [33] as UK data were not available. EuroQol (EQ-5D) utility values for the progression-free and progresseddisease health states were not available in a representative sample of the UK population. Instead, based on the NICE ERG recommendation, US-based utility values were adjusted by NICE ERG to 0.742 (from 0.800) for progression-free disease and 0.671 (from 0.750) for progresseddisease, to reflect the UK context. Neutropenia, thrombocytopenia, and leukopenia were assumed to be asymptomatic and not to have an impact on health-related quality of life. 
Analysis Plan
Following a stepwise procedure, we compared the various treatment options in terms of costs and outcomes to determine which treatment comparison to retain. Second, we identified the dominant regimens that were less costly but more effective in terms of QALYs and LYs gained compared with other regimens. Third, we eliminated regimens that were dominated by other less-costly and more effective regimens. Finally, we used non-rounded costs and outcomes to calculate the ICUR/ICER values. The likelihood of the regimens being cost effective against GEM across a range of willingness-to-pay values was assessed using the costeffectiveness acceptability curve (CEAC).
Sensitivity Analyses
Probabilistic sensitivity analysis (PSA) was used to address the uncertainty in parameters. Parameters were entered as probability distributions instead of mean values, and samples were randomly selected from each distribution. Correlations between these parameters were not taken into consideration. Costs, QALYs, and LYs were calculated for the simulation, and the process was repeated 2000 times. ICURs from each of these simulations were calculated against GEM. Distributions specific for each parameter in the model are described in detail in our economic evaluation for the UK of NAB-P + GEM versus GEM [11] , and are summarized in the ESM. One-way sensitivity analyses (OWSA) were run for the most cost-effective regimen to consider variations in the ICURs when ranges of parameter values are considered independently. These parameters included the OS HR, the PFS HR, the progression-free disease utility, the progressed-disease utility, and the costs of adverse event management, febrile neutropenia, and drug acquisition. The upper and lower confidence interval values were used for these parameters, except for drug acquisition cost, where 10% variation was used.
Results
Test of the Proportional Hazard Assumption
The proportional hazard assumption was found to be invalid between FFX and NAB-P + GEM, for both the OS and PFS data, as the curves crossed (Electronic Supplementary  Figs. S2 and S3) . Hence, OS and PFS survival data for NAB-P + GEM were obtained individually from the MPACT trial using the Weibull parametric model [8] .
Cost-Effectiveness Results
The least costly regimen was GEM (£10,326), followed by CAP + GEM (£12,261), CIS + GEM (£14,208), OX + GEM (£14,887), FFX (£18,456), and NAB-P + GEM (£20,806) ( Table 2) . Table 3 shows the ICURs/ICERs for FFX and CAP + GEM against GEM alone. Compared with GEM, the ICUR for CAP + GEM was £28,066 and the ICUR for FFX was £33,020/QALY gained; compared with GEM, the ICER for CAP + GEM was £17,437 and the ICER for FFX was £22,291/LY gained; and compared with CAP + GEM, the ICUR for FFX was £34,947/QALY gained and the ICER was £24,414/LY gained. Hence, FFX was extendedly dominated by CAP at a threshold value of £30,000/QALY. PSA results confirmed the base-case results All 2000 simulations from the PSA resulted in additional costs and benefits for FFX over GEM (the top-right quadrant of the cost-effectiveness plane) (Fig. 1) . For CAP + GEM, most of the simulations resulted in additional costs and benefits over GEM, while some resulted in additional benefits at lower costs (the lower-right quadrant of the cost-effectiveness plane).
The CEAC curves show the likelihood of FFX and CAP + GEM being cost effective compared with GEM when CAP capecitabine, CIS cisplatin, GEM gemcitabine, HRG Healthcare Resource Groups, NAB-P nab-paclitaxel, OX oxaliplatin, FFX FOLFIRINOX, 5-FU 5-fluorouracil, HR hazard ratio [32] considered across a range of willingness-to-pay thresholds for the cost/QALY gained (Fig. 2) . The CEAC plot shows that FFX and CAP + GEM have an approximately 36 and 72% likelihood of being cost effective, respectively, compared with GEM at a willingness-to-pay threshold of £30,000/QALY. At any willingness-to-pay threshold above £36,000/QALY, FFX has a higher likelihood of being cost effective compared with CAP + GEM. Figure 3 show the results for the seven OWSAs with the greatest effects on the base-case ICUR for CAP + GEM and FFX against GEM. OWSAs showed that the key driver of the cost effectiveness of CAP + GEM and FFX was the OS benefit. Most ICURs for CAP + GEM were within £10,000 and £65,000/QALY gained, while most ICURs for FFX were within £25,000 and £50,000/QALY gained. The ICUR for FFX against GEM decreased to £20,128/QALY gained, while the ICUR for CAP + GEM against GEM decreased to £21,048/QALY gained if drug costs were decreased by 50%.
One-Way Sensitivity Analysis
Secondary Analyses
The impact of wastage using whole vial costs rather than milligrams costs is summarized in Table 4 . The ICUR for FFX against GEM increased from £33,020/QALY to £41,111/QALY gained, while the ICUR for CAP + GEM against GEM decreased from £28,066/QALY to £22,976/ QALY gained.
Discussion
This independent economic evaluation for the UK used data from published clinical trial reports and a network metaanalysis to estimate the treatment effects and evaluate associated economic implications of OX + GEM, CIS + GEM, CAP + GEM, FFX, and NAB-P + GEM in the treatment of MPC. Summarized, NAB-P + GEM, OX + GEM, and CIS + GEM were dominated by FFX and CAP + GEM. Treatment with either FFX or CAP + GEM was more costly, but also more effective, than with GEM; however, the FFX ICUR was 1.17 times higher than the CAP + GEM ICUR. Our findings confirmed the concerns of the NICE external ERG regarding the validity of the proportional hazard assumption between NAB-P + GEM and FFX. They also corresponded closely to those reported in the manufacturer's submission regarding NAB-P + GEM against FFX and CAP + GEM. Although the comparison of costs, ICURs, or ICERs for studies from different countries may not be meaningful, similar efficacy, in terms of QALY and LY gained, was reported in a recent economic evaluation study in Canada [35] .
Translating our findings to both the UK healthcare financing system and the NICE system of applying thresholds to guide reimbursement, NAB-P + GEM, CIS + GEM and OX + GEM do not meet cost-effectiveness criteria in absolute terms. CAP + GEM and FFX are less costly and clinically more effective options. Of these two regimens, CAP + GEM meets the commonly applied UK threshold for cancer drugs of £30,000/QALY. The NICE Appraisal Committee accepted that combination regimens meet the end-of-life criteria when compared against GEM alone, but did not consider them to meet the end-of-life criteria when compared against each other. The end-of-life criteria allow interventions with an ICER over £30,000QALY to be recommended. FFX fails this threshold condition against CAP + GEM, but would be cost effective at thresholds of £36,000/QALY against GEM alone and at £34,947/ QALY against CAP + GEM [36] .
Considering this, the decision of the NHS to not fund the NAB-P + GEM, FFX, and OX + GEM treatment options may pose a challenge as these regimens are accessible in the US and other European countries. For example, between 2004 and 2008, 46 anticancer drugs were granted a European license following European Medicines Agency approval. NICE recommended that 18 (39%) of these drugs be freely available in the NHS, with 11 (24%) still awaiting approval over the study period. In contrast, the three main insurance providers in the US covered all of these drugs [37, 38] . Furthermore, within the UK, discrepancies are evident. For example, although FFX is not approved for MPC treatment by either NICE in England and Wales, or the Scottish Medicines Consortium, some centers in the UK offer it to MPC patients upon approval from the local NHS Primary Care Trust [39] . Drummond and Towse have argued that the demand for cancer drugs is not price-sensitive as the decision regarding treatment is not made by uninformed patients, but rather by their informed physician [40] . Moreover, cancer is a lifethreatening condition where patients are willing to receive and pay for therapies, even those with a marginal benefit, as in the case for the MPC treatment options evaluated here [41] . In fact, patients are willing to pay for cancer treatments that provide increased benefits in terms of disease control, survival, and quality of life [42, 43] . This willingness varies by socioeconomic group [40] , and the demand for a particular cancer treatment does not come from an unbiased evaluation of benefit and risk, but rather from hope and insight, even when challenged with high toxicity or low benefit [44] . Considering further the safety data from the respective clinical trials, the toxicity profile and survival benefit associated with FFX may make it the preferable option for younger patients with good performance status. Conversely, NAB-P + GEM might be more suitable for a greater range of patients due to its efficacy and tolerability profile [45] . This extends the decision about funded (and unfunded) to a level of clinical granularity that the respective trial findings allude to, but for which these trials do not provide a firm evidence base.
However, our analysis has limitations. Our model assumptions were validated by one medical oncologist rather than an expert panel. In the absence of direct comparative trial evidence, we relied on data from a published network meta-analysis [12] to estimate the efficacy between FFX and other regimens. Issues such as bias, trial heterogeneity, and inconsistency may have impacted the results of the network meta-analysis and, by extension, our economic evaluation. The network meta-analysis assumed consistency between the clinical trials included, however inconsistency remains a methodological issue for multiple treatment comparisons as different study populations, interventions, trial designs, and outcome definitions introduce potential confounding bias to the analysis, and baseline differences in trial populations may affect outcomes. For example, some studies included patients with locally advanced cancer or MPC, whereas other studies were limited to patients with metastatic disease only. Patients with locally advanced unresectable disease have a longer median survival than patients with metastatic disease [46] . In addition, some studies specified an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 for inclusion criteria, whereas others specified a Karnofsky score ≥ 70, which may imbalance the performance score between the included studies. There were some discrepancies between the patient characteristics included in the model and the British patients diagnosed with pancreatic cancer in the UK (Electronic Supplementary Table S1 ). We could not assess the proportional hazard assumption between FFX and the other regimens (CAP + GEM, CIS + GEM, and OX + GEM) as the survival data were reported in more than one clinical trial and the only method to include them in the model was through the indirect HR comparison reported in the network meta-analysis. Lastly, the UK has a unique healthcare financing system where the government pays most of the treatment cost, and, as such, the utility estimates in this model were specific to this country. Therefore, the findings cannot be generalized beyond the UK setting. Country-specific economic evaluations must be conducted wherever these regimens are commonly used in practice, to attain economic estimates for these countries.
Conclusions
In this independent economic evaluation for the UK, the superior survival efficacies of CAP + GEM and FFX were associated with additional costs, and over other treatment regimens. At the commonly applied threshold value of £30,000/QALY, CAP + GEM was considered to be the only cost-effective regimen in the management of MPC in the UK.
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